The findings suggest that YAP activation due to NF2 loss mediates resistance to Bcl-xL inhibitors in Rasa1 deficient cells and highlights the potential of combining YAP and Bcl-xL inhibitors for treatment of highly metastatic GC. Here, RASA1 is linked to gastric cancer.